Mellott CE, Jaworski R, Carrico J, Talbird SE, Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712
Falope O, Nyaku MK, O'Rourke C, Hermany LV, Plavchak B, Mauskopf J, Hartley L, Kruk ME. Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs. Expert Rev Vaccines. 2022 Nov 1;21(11):1621-36. doi: 10.1080/14760584.2022.2116007
Poulos C, Boeri M, Coulter JR, Huang L, Schley K, Pugh SJ. Travelers' preferences for tick-borne encephalitis vaccination. Expert Rev Vaccines. 2022 Oct 1;21(10):1495-504. doi: 10.1080/14760584.2022.2108798
Clinch S, McDougall F, Barrett A, Olayinka-Amao B, Craveiro L, Baker M, Lindemann M. A patient-focused qualitative study to support content validity of digital performance assessments in MS. Poster presented at the 2021 ECTRIMS Annual Congress; October 13, 2021. [abstract] Mult Scler J Exp Transl Clin. 2021 Oct 21; 27(2 Suppl):329. doi: 10.1177/13524585211044667
Patterson BJ, Myers K, Stewart A, Mange B, Hillson EM, Poulos C. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. Expert Rev Vaccines. 2021 Jul 22. doi: 10.1080/14760584.2021.1910502
Huang L, Mauskopf J, Farkouh R, Masaquel C. Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, The Netherlands, and Canada. Expert Rev Vaccines. 2021 Jan;20(1):59-72. doi: 10.1080/14760584.2021.1878030
Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020 Jan;9(2):1-14. doi: 10.1177/2055217320910778
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.